M&A Deal Summary

Eurazeo PME, Merieux Equity Partners, SK Capital Partners and Ardian Acquire Seqens

On March 21, 2016, private equity firm Eurazeo PME, growth capital firm Merieux Equity Partners, private equity firm SK Capital Partners and private equity firm Ardian acquired chemicals company Seqens from Ardian

Acquisition Highlights
  • This is Eurazeo PME’s 3rd, Merieux Equity Partners’ 1st, SK Capital Partners’ 7th and Ardian’s 9th transaction in the Chemicals sector.
  • This is Eurazeo PME’s 27th, Merieux Equity Partners’ 3rd, SK Capital Partners’ 1st and Ardian’s 132nd transaction in France.

M&A Deal Summary

Date 2016-03-21
Target Seqens
Sector Chemicals
Buyer(s) Eurazeo PME
Merieux Equity Partners
SK Capital Partners
Ardian
Sellers(s) Ardian
Deal Type Secondary Buyout

Target

Seqens

Ecully, France
Seqens is a global diversified chemicals Group that produces and distributes essential chemicals that are used in everyday products. Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Seqens was founded in 2003 and is based in Ecully, France.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 4

Buyer
DESCRIPTION

Eurazeo PME, formerly known as OFI Private Equity Capital. Eurazeo PME invests equity and mezzanine capital in secondary buyout transactions of unlisted French companies. The Firm looks for opportunities valued between €50 and €250 million. Areas of interest include chemicals, financial services, consumer services, retail, manufacturing, distribution, and life science. Eurazeo PME was formed in 1997 and is based in Paris.


DEAL STATS #
Overall 33 of 85
Sector: Chemicals M&A 3 of 5
Type: Secondary Buyout M&A Deals 14 of 34
Country: France M&A 27 of 57
Year: 2016 M&A 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-11 Orolia

Les Ulis, France

Orolia provides resilient positioning, navigation, and timing (PNT) solutions which improve the reliability, performance, and safety of critical civilian, military and space operations, including in harsh or altered Global Navigation Satellite System (GNSS) environments. The company has a broad portfolio of technologies across the Resilient PNT value-chain with full system capabilities, and is a provider of PNT equipment, simulation and test solutions. It is also providing emergency locator beacons for commercial aviation and military applications. Orolia was formed in 2006 and is based in Les Ulis, France.

Buy €100M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-04 Linvosges

Gerardmer, France

Linvosges offers linen products like sheets, fitted sheets and other products. Linvosges was founded in 1922 and is based in Gerardmer, France.

Buy -
Buyer

Merieux Equity Partners

Investor Investor Investor Investor


Category Growth Capital Firm
Founded 2009
PE ASSETS 1.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

Mérieux Développement SAS is a venture and growth capital investment firm associated with family holding company Institut Mérieux. The Firm focuses on the health and nutrition sectors and will consider opportunities throughout North America and Europe. Mérieux Développement SAS was established in 2009 and is headquartered in Lyon, France.


DEAL STATS #
Overall 4 of 24
Sector: Chemicals M&A 1 of 2
Type: Secondary Buyout M&A Deals 2 of 6
Country: France M&A 3 of 14
Year: 2016 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-05 Kalila Medical

Campbell, California, United States

Kalila Medical, Inc. is a medical device company developing next-generation access technologies used in cardiac electrophysiology procedures for the treatment of heart rhythm disorders, including atrial fibrillation.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-01 Swixx Biopharma

Baar, Switzerland

Swixx BioPharma is a specialized distributor of rare diseases, Rx and OTC medicinal products in Central & Eastern Europe, and acts as a true commercialization partner for Biotech & Pharma companies in this area. Swixx Biopharma was founded in 2014 and is based in Baar, Switzerland.

Buy -
Buyer

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.


DEAL STATS #
Overall 12 of 44
Sector: Chemicals M&A 7 of 21
Type: Secondary Buyout M&A Deals 2 of 10
Country: France M&A 1 of 3
Year: 2016 M&A 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-11 Extractas Bioscience

Westbury, Australia

Extractas Bioscience is a provider in agricultural R&D and the extraction and purification of high-value plant-derived products, with a particular focus on alkaloid raw materials used in the production of active pharmaceutical ingredients. Extractas Bioscience was founded in 1975 and is based in Westbury, Australia.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-20 Noramco

Wilmington, Delaware, United States

Noramco is a provider in the production of controlled substances for the pharmaceutical industry, for medicines used to treat Attention Deficit Hyperactivity Disorder, pain, addiction, and for abuse-deterrent formulations. Noramco was founded in 1979 and is based in Wilmington, Delaware.

Buy -
Buyer

Ardian

Paris, France

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1996
PE ASSETS 127.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Ardian is a mega-sized diversified investment group focused on opportunities worldwide. Ardian invests across and manages funds focused on small and mid-sized buyouts, growth capital financings, mezzanine, infrastructure, real estate, and co-investment opportunities. Ardian's small-buyouts group targets controlling interests in French, German, and Italian businesses valued up to €100 million. It's mid-sized buyout group seeks businesses valued up €1.5 billion and does not have any geographic limitations. The Infrastructure team looks for European opportunities and can commit up to €1 billion per transaction. The Mezzanine group supports junior capital commitments of €5 to €80 million. In addition to direct investing, Ardian also manages various private equity fund-of-funds. Ardian was founded in 1996 and is based in Paris.


DEAL STATS #
Overall 264 of 464
Sector: Chemicals M&A 9 of 11
Type: Secondary Buyout M&A Deals 80 of 155
Country: France M&A 132 of 206
Year: 2016 M&A 10 of 34
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-18 Grand Frais

Givors, France

Grand Frais is a fresh food retail specialist, offering under one roof an extensive selection of quality fresh products (fruits & vegetables, seafood, meat, dairy and grocery). Grand Frais was founded in 1992 and is based in Givors, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 CGE Palea Arsa

Rovereto, Italy

CGE Palea Arsa is a ground based solar plant with an installed capacity of 9.6MW. CGE Palea Arsa is based in Rovereto, Italy.

Buy -

Seller(S) 1

SELLER

Ardian

Paris, France

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1996
PE ASSETS 127.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Ardian is a mega-sized diversified investment group focused on opportunities worldwide. Ardian invests across and manages funds focused on small and mid-sized buyouts, growth capital financings, mezzanine, infrastructure, real estate, and co-investment opportunities. Ardian's small-buyouts group targets controlling interests in French, German, and Italian businesses valued up to €100 million. It's mid-sized buyout group seeks businesses valued up €1.5 billion and does not have any geographic limitations. The Infrastructure team looks for European opportunities and can commit up to €1 billion per transaction. The Mezzanine group supports junior capital commitments of €5 to €80 million. In addition to direct investing, Ardian also manages various private equity fund-of-funds. Ardian was founded in 1996 and is based in Paris.


DEAL STATS #
Overall 116 of 247
Sector: Chemicals M&A 5 of 9
Type: Secondary Buyout M&A Deals 41 of 92
Country: France M&A 57 of 116
Year: 2016 M&A 8 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-18 Grand Frais

Givors, France

Grand Frais is a fresh food retail specialist, offering under one roof an extensive selection of quality fresh products (fruits & vegetables, seafood, meat, dairy and grocery). Grand Frais was founded in 1992 and is based in Givors, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 CGE Palea Arsa

Rovereto, Italy

CGE Palea Arsa is a ground based solar plant with an installed capacity of 9.6MW. CGE Palea Arsa is based in Rovereto, Italy.

Buy -